[go: up one dir, main page]

HUP0302233A3 - Methods of treating viral diseases with il-18 and il-18 combinations - Google Patents

Methods of treating viral diseases with il-18 and il-18 combinations

Info

Publication number
HUP0302233A3
HUP0302233A3 HU0302233A HUP0302233A HUP0302233A3 HU P0302233 A3 HUP0302233 A3 HU P0302233A3 HU 0302233 A HU0302233 A HU 0302233A HU P0302233 A HUP0302233 A HU P0302233A HU P0302233 A3 HUP0302233 A3 HU P0302233A3
Authority
HU
Hungary
Prior art keywords
combinations
methods
viral diseases
treating viral
treating
Prior art date
Application number
HU0302233A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP0302233A2 publication Critical patent/HUP0302233A2/hu
Publication of HUP0302233A3 publication Critical patent/HUP0302233A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HU0302233A 2000-06-02 2001-06-01 Methods of treating viral diseases with il-18 and il-18 combinations HUP0302233A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20886900P 2000-06-02 2000-06-02
PCT/US2001/017924 WO2001093898A1 (en) 2000-06-02 2001-06-01 Methods of treating viral diseases with il-18 and il-18 combinations

Publications (2)

Publication Number Publication Date
HUP0302233A2 HUP0302233A2 (hu) 2003-10-28
HUP0302233A3 true HUP0302233A3 (en) 2006-11-28

Family

ID=22776366

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302233A HUP0302233A3 (en) 2000-06-02 2001-06-01 Methods of treating viral diseases with il-18 and il-18 combinations

Country Status (17)

Country Link
US (1) US20030113292A1 (hu)
EP (1) EP1296707A4 (hu)
JP (1) JP2004514652A (hu)
KR (1) KR20030007840A (hu)
CN (1) CN1457258A (hu)
AU (2) AU2001275166B2 (hu)
BR (1) BR0111393A (hu)
CA (1) CA2411354A1 (hu)
CZ (1) CZ20023921A3 (hu)
HU (1) HUP0302233A3 (hu)
IL (1) IL153201A0 (hu)
MX (1) MXPA02011969A (hu)
NO (1) NO20025722L (hu)
NZ (1) NZ523123A (hu)
PL (1) PL363166A1 (hu)
WO (1) WO2001093898A1 (hu)
ZA (1) ZA200209757B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481890A1 (en) * 2002-06-27 2004-01-08 Medivir Ab Synergistic interaction of abacavir and alovudine
US20050079153A1 (en) * 2002-08-14 2005-04-14 Pfizer Inc. Methods for enhancing immune functions in neonatal mammals by administration of IL-18
EP1572228A4 (en) * 2002-09-19 2009-03-04 Centocor Inc METHOD FOR THE INTRODUCTION OF THE TREATMENT OF DENDRITIC CELLS AND ITS USES
DE602004031681D1 (de) * 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ATE426410T1 (de) * 2004-08-20 2009-04-15 Smithkline Beecham Corp Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
EP2059253A4 (en) 2006-09-14 2011-09-14 Univ Pennsylvania MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18
ES2310129B1 (es) 2007-06-01 2009-10-02 Juan Carlos Garcia Saban Nueva superficie de implantes metalicos a base de titanio destinados a ser insertado en tejido oseo.
ES2315194B1 (es) 2007-09-10 2010-02-26 Francisco J. GARCIA SABAN Procedimiento para obtener una nueva superficie de un implante metalico a base de titanio destinado a ser insertado en tejido oseo.
CN104474534A (zh) * 2014-12-22 2015-04-01 哈德逊(天津)生物技术有限责任公司 白介素-18抗病毒口腔喷剂
BR112020004389A2 (pt) 2017-09-06 2020-09-08 Yale University composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo.
TW202233657A (zh) 2020-11-02 2022-09-01 美商辛卡Il 18公司 介白素-18變體及使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW581771B (en) * 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide

Also Published As

Publication number Publication date
IL153201A0 (en) 2003-07-06
JP2004514652A (ja) 2004-05-20
NO20025722D0 (no) 2002-11-28
WO2001093898A1 (en) 2001-12-13
NO20025722L (no) 2003-01-24
BR0111393A (pt) 2004-08-24
PL363166A1 (en) 2004-11-15
EP1296707A4 (en) 2004-03-17
EP1296707A1 (en) 2003-04-02
KR20030007840A (ko) 2003-01-23
NZ523123A (en) 2005-12-23
MXPA02011969A (es) 2004-09-06
CZ20023921A3 (cs) 2003-10-15
CA2411354A1 (en) 2001-12-13
ZA200209757B (en) 2004-10-04
US20030113292A1 (en) 2003-06-19
AU7516601A (en) 2001-12-17
HUP0302233A2 (hu) 2003-10-28
CN1457258A (zh) 2003-11-19
AU2001275166B2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
GB0111872D0 (en) Therapeutic agents and methods
IL162533A0 (en) Chalcone derivatives and their use to treat diseases
AU6118001A (en) Combination therapeutic compositions and methods of use
IL150468A0 (en) Improved micro-needles and methods of manufacture and use thereof
IL148034A0 (en) Methods of treating nuclear factor-kappa b mediated diseases and disorders
AU4244200A (en) Multi-functional therapeutic compress and methods of using the same
IL153574A0 (en) Methods of treating neutrophil-related diseases with topical anesthetics
AU2002346504A8 (en) Therapeutic protein and treatments
AU8136801A (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
AU7516601A (en) Methods of treating viral diseases with il-18 and il-18 combinations
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
IL148202A0 (en) Copolymers and methods of treating prion-related diseases
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
GB0012186D0 (en) Treatment of cancer and neurological diseases
HK1055243A (en) Methods of treating viral diseases with il-18 and il-18 combinations
GB0018887D0 (en) Compound and their therapeutic use
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
HUP0302882A3 (en) Improved specificity in treatment of diseases
GB2381455B (en) Treatment of burns
EP1303281A4 (en) METHODS OF TREATMENT
EP1392460A4 (en) AMINOSILANOL HYDROFLUORIDES AND THEIR USE
AU6884801A (en) Therapeutic compounds and methods
EP1210111A4 (en) DNA OF GAMMA HERPESVIRUS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees